Molnupiravir Current Affairs, GK & News

Molnupiravir

October 13, 2021

Molnupiravir is an orally effective experimental antiviral drug developed to treat the influenza flu. It is a prodrug of the synthetic nucleoside derivative N4hydroxycitidine and by introducing copy errors during viral RNA replication it exerts its antiviral effect. Highlights The drug was developed at Emory University by the university’s pharmaceutical innovation company, Drug Innovation Ventures ..

..Read More

Precautionary vaccine jabs in India

January 11, 2022

The Government of India is to provide third dose of vaccine. This third dose has been named “precaution dose” or booster dose. About the precaution dose The health care workers, comorbid patients (people with severe medical conditions) and frontline workers are eligible to get the precaution dose. Five states in the country are to go ..

Month: 

Category: 

Topics:  • • • • • • • • • • • • • • • • •

Molnupiravir

November 5, 2021

Molnupiravir is used to treat COVID-19. It is sold under the brand name Lagevrio. It inhibits the replication of RNA viruses. About Molnupiravir The Molnupiravir is a prodrug. Prodrug means a compound that is used to improve the absorption, distribution, metabolization and excretion of a drug. It is used to improve the bioavailability when the ..

Topics: 

Molnupiravir: New drug to treat COVID-19

October 4, 2021

On October 1, 2021, Pharmaceutical company “Merck and Ridgeback Biotherapeutics” announced the early results of Phase-3 trials of its anti-viral drug called molnupiravir. As per the results, Molnupiravir has reduced the chances of hospitalisation by half among COVID-19 patients with mild or moderate symptoms. Highlights Placebo trials comprised of testing a drug on thousands of ..

Month: 

Category: 

Topics:  • • • •